Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
Dr Philipson has over 25 years of industry experience and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines and executing clinical development programs across all phases of development. He also brings in-depth knowledge of regulatory strategy in drug development. Dr Philipson most recently was CMO of Calliditas Therapeutics and previously spent 16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head in the Rare Diseases Unit. He also has experience from Takeda, and a 4-year period as CMO at Trizell.
"We are very pleased to welcome Dr Philipson to the executive management team as CMO. He brings invaluable experience in the area of drug development, from first-in-human to Phase 3, and post-approval studies; with expertise across rare diseases, inflammation and oncology, which will be critical as we prepare for the next phase of our development," said CEO Renée Aguiar-Lucander.
"I am excited to have the opportunity to join Hansa at this stage of the company's development. I look forward to working with the Hansa team and leveraging my experience from prior roles to support upcoming regulatory submissions and help build a strategic development plan for future indications," said Dr Philipson.
Contacts for more information:Evan Ballantyne, Chief Financial OfficerIR@hansabiopharma.comStephanie Kenney, VP Global Corporate Affairsmedia@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer,c4204433
The following files are available for download:
https://mb.cision.com/Main/1219/4204433/3573033.pdf
20250708-CMO_ENG_FINAL
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer-302499853.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
Veeva Systems VEEV is leaning heavily on its Vault R&D platform to anchor long-term growth, and so far, it's working. The platform, which spans clinical, regulatory, quality, and safety domains, continues to see healthy customer expansion and product adoption. In its latest update, management highlighted strength in areas like Vault Safety and Vault Clinical, where digitization and automation are reshaping how trials are run and managed. Veeva's deep relationships with top pharma clients, combined with ongoing investments in domain-specific AI, are helping it evolve from a software vendor into a strategic infrastructure partner across the drug development lifecycle. Still, the landscape is changing. AI-native challengers are emerging with new ways to approach trial design, drug safety monitoring and data workflows. While Veeva is embedding AI across its R&D suite, supporting functions like regulatory document drafting and case processing, it's now competing not only with traditional players, but also with younger, more specialized platforms. The company's scale, focus on compliance, and integration depth remain strong differentiators, but investors will want to see continued innovation and proof that Veeva can hold its lead in an increasingly dynamic and data-driven market. Peers Update A name to watch in this space is Dassault Systemes DASTY, which operates Medidata, a major provider of cloud-based solutions for clinical trials. Medidata is expanding its capabilities through AI-powered tools for trial planning and patient recruitment. While its approach differs from Veeva's, both companies are addressing similar challenges in trial efficiency and data quality. Dassault also brings strength in simulation and manufacturing through its broader 3DEXPERIENCE platform, offering customers a more holistic lens on product development. Another adjacent player is Schrodinger Inc. SDGR, known for its AI-driven drug discovery platform. While Schrödinger operates earlier in the R&D value chain, its traction with biopharma clients reflects the growing demand for specialized, cloud-first tools in life sciences. As R&D organizations diversify their tech stacks, companies like Schrödinger could complement, not necessarily compete with, platforms like Veeva, particularly in environments where speed and innovation are prioritized. Veeva Systems' Price Performance, Valuation and Estimates Shares of VEEV have gained 35.4% in the year-to-date period compared with the industry's growth of 10.7%. Image Source: Zacks Investment Research From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.2, above the industry average. VEEV carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dassault Systemes SA (DASTY) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Schrodinger, Inc. (SDGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
8 hours ago
- Yahoo
Study reveals the foods which help avoid illness in later life
What you eat could determine how many chronic illnesses you get later in life, scientists warn. Research has revealed that a healthy diet - such as the Mediterranean diet which is high in plants, fish and unsaturated fats - could slow down the accumulation of chronic diseases including dementia in older adults. Inflammatory diets full of processed meat and sugar may accelerate it. Researchers from Karolinska Institutet in Sweden studied four diets to investigate their impact on chronic diseases in older adults. Three of the diets studied were healthy and focused on the intake of vegetables, fruit, whole grains, nuts, legumes, unsaturated fats and reduced intake of sweets, red meat, processed meat and butter/margarine. The fourth diet, however, was pro-inflammatory and focused on red and processed meat, refined grains and sweetened beverages, with lower intake of vegetables, tea and coffee. Researchers followed the diets of 2,400 adults aged 60 and older in Sweden for 15 years and tracked their chronic conditions. Dietary intake was measured using food frequency questionnaires, and adherence to four dietary patterns: the Empirical Dietary Inflammatory Index (EDII), AHEI, the Alternate Mediterranean Diet (AMED), and the MIND (Mediterranean–DASH Intervention for Neurodegenerative Delay). Multimorbidity was defined as the number of chronic diseases and grouped by organ system - musculoskeletal, cardiovascular, and neuropsychiatric. The results published in the journal Nature Aging revealed those who followed the healthy diets had a slower development of chronic diseases. For example, long-term adherence to healthy dietary patterns, particularly the AMED, AHEI, and MIND, was linked to a slower accumulation of chronic diseases in older adults. This applied to cardiovascular disease and dementia, but not to diseases related to muscles and bones. But those who followed the pro-inflammatory diet, on the other hand, increased their risk of chronic diseases. 'Our results show how important diet is in influencing the development of multimorbidity in ageing populations,' said co-first author Adrián Carballo-Casla, postdoctoral researcher at the Aging Research Centre, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet. The protective effects of diet may be explained by reduced inflammation, a key factor in aging-related diseases. Study authors want to further their research by identify the dietary recommendations that may have the greatest impact on longevity and the groups of older adults who may benefit most from them, based on their age, gender, psychosocial background and chronic diseases.
Yahoo
12 hours ago
- Yahoo
BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is . On July 11, BofA Securities initiated coverage of the stock with a 'Buy' rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company's Taysha gene therapy TSHA-102 under development for Rett Syndrome. Copyright: dolgachov / 123RF Stock Photo The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones. Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity. Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotech company focused on developing and bringing to market gene therapies for serious monogenic disorders affecting the central nervous system. It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies. While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
